Delivery Order SPE2DB20D3103-SPE2DB21FL8Z9
- Not listed
- This federal contract award is for a Prime Vendor Pharmaceutical Branch in Philadelphia, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract, valued at $1,277.94, is a Delivery Order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for...
- This federal contract award is for a Delivery Order (DO) from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The DO, valued at $8,991.26, is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award is from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,472.46 delivery order is for a "Prime Vendor Pharm Branch-Philadelphia" and has a completion date of September 29, 2020. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,312.68, is a Delivery Order (DO) awarded under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. The IDC, valued up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,116.60 firm-fixed-price delivery order supports the Prime Vendor Pharmacy Branch-Philadelphia program. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables Amerisourcebergen to...
- This federal contract award is a delivery order valued at $1,643.52 issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for a Prime Vendor Pharmaceutical Branch in Philadelphia and does not have a set-aside designation, indicating open competition. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the provision of a prime vendor pharmaceutical branch in Philadelphia for the Defense Logistics Agency (DLA). The $11,636.45 delivery order contract has a firm fixed price and runs through November 2020. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to supply a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the provision of a Prime Vendor Pharmaceutical Branch in Philadelphia. The $11,121.26 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a...
- This federal contract award is a delivery order worth $3,462.33 issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for providing a prime vendor pharmaceutical support to the DLA Troop Support Medical branch in Philadelphia, Pennsylvania. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the...
- This federal contract award, issued by the Defense Logistics Agency (DLA), is for a pharmaceutical prime vendor delivery order with Amerisourcebergen Drug Corp as the prime contractor. The $1,214.11 firm fixed-price contract is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00, that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FL8Z9Delivery Order
This federal contract award is for a Delivery Order (DO) valued at $11,123.88, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for a Prime Vendor Pharmaceutical Branch in Philadelphia, with an ultimate completion date of December 18, 2020. This DO is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The contract was awarded without any set-aside designations, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 12/17/20 |